Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

NCT03011814 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03011814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03011814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 8, 2017
Completion date
April 14, 2030
Enrollment
78 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

folliculotropic mycosis fungoides, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent mature t- and nk-cell non-hodgkin lymphoma, recurrent mycosis fungoides, refractory cutaneous t-cell non-hodgkin lymphoma, refractory mycosis fungoides, refractory peripheral t-cell lymphoma, not otherwise specified, sezary syndrome